Kane Biotech Inc. (KNBIF)
USD 0.06
(0.0%)
USD 0.06
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.27 Million CAD | 35.04% |
| 2022 | 6.85 Million CAD | 45.43% |
| 2021 | 4.71 Million CAD | 109.56% |
| 2020 | 2.24 Million CAD | 1224.93% |
| 2019 | 169.81 Thousand CAD | -66.04% |
| 2018 | 500 Thousand CAD | 0.0% |
| 2017 | - CAD | -100.0% |
| 2016 | 479.99 Thousand CAD | 9.43% |
| 2015 | 438.64 Thousand CAD | -2.2% |
| 2014 | 448.5 Thousand CAD | 8.53% |
| 2013 | 413.24 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| 2005 | - CAD | 0.0% |
| 2004 | - CAD | 0.0% |
| 2003 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 9.19 Million CAD | 0.53% |
| 2024 Q2 | 2.38 Million CAD | -74.05% |
| 2023 Q4 | 9.14 Million CAD | -0.48% |
| 2023 Q3 | 9.19 Million CAD | 14.25% |
| 2023 Q1 | 7.92 Million CAD | 15.63% |
| 2023 FY | 9.21 Million CAD | 34.34% |
| 2023 Q2 | 8.04 Million CAD | 1.48% |
| 2022 Q2 | 6.72 Million CAD | 37.1% |
| 2022 FY | 6.85 Million CAD | 45.43% |
| 2022 Q1 | 4.9 Million CAD | 4.03% |
| 2022 Q3 | 6.74 Million CAD | 0.3% |
| 2022 Q4 | 6.85 Million CAD | 1.66% |
| 2021 FY | 4.71 Million CAD | 109.56% |
| 2021 Q2 | 3.5 Million CAD | 58.82% |
| 2021 Q3 | 4.64 Million CAD | 32.62% |
| 2021 Q4 | 4.71 Million CAD | 1.42% |
| 2021 Q1 | 2.2 Million CAD | -1.9% |
| 2020 FY | 2.24 Million CAD | 1224.93% |
| 2020 Q1 | 307 Thousand CAD | 80.78% |
| 2020 Q2 | 537.39 Thousand CAD | 75.05% |
| 2020 Q3 | 746.49 Thousand CAD | 38.91% |
| 2020 Q4 | 2.24 Million CAD | 201.4% |
| 2019 Q1 | 500 Thousand CAD | 0.0% |
| 2019 FY | 169.81 Thousand CAD | -66.04% |
| 2019 Q3 | 647.37 Thousand CAD | 29.48% |
| 2019 Q2 | 500 Thousand CAD | 0.0% |
| 2019 Q4 | 169.81 Thousand CAD | -73.77% |
| 2018 Q3 | 500 Thousand CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 FY | 500 Thousand CAD | 0.0% |
| 2018 Q4 | 500 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2017 Q2 | 914.79 Thousand CAD | 85.96% |
| 2017 Q1 | 491.93 Thousand CAD | 2.49% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 FY | - CAD | -100.0% |
| 2017 Q3 | - CAD | -100.0% |
| 2016 Q2 | 457.78 Thousand CAD | -35.8% |
| 2016 FY | 479.99 Thousand CAD | 9.43% |
| 2016 Q1 | 713.04 Thousand CAD | 62.56% |
| 2016 Q4 | 479.99 Thousand CAD | 2.48% |
| 2016 Q3 | 468.4 Thousand CAD | 2.32% |
| 2015 Q2 | 478.52 Thousand CAD | 3.36% |
| 2015 Q1 | 462.99 Thousand CAD | 3.23% |
| 2015 Q3 | 495.5 Thousand CAD | 3.55% |
| 2015 Q4 | 438.64 Thousand CAD | -11.47% |
| 2015 FY | 438.64 Thousand CAD | -2.2% |
| 2014 Q3 | 434.62 Thousand CAD | 3.02% |
| 2014 Q4 | 448.5 Thousand CAD | 3.19% |
| 2014 Q1 | 410.12 Thousand CAD | -0.76% |
| 2014 FY | 448.5 Thousand CAD | 8.53% |
| 2014 Q2 | 421.87 Thousand CAD | 2.87% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | 413.24 Thousand CAD | 0.0% |
| 2013 Q4 | 413.24 Thousand CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 FY | - CAD | 0.0% |
| 2007 Q1 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2006 Q2 | - CAD | 0.0% |
| 2006 Q1 | - CAD | 0.0% |
| 2006 FY | - CAD | 0.0% |
| 2006 Q4 | - CAD | 0.0% |
| 2006 Q3 | - CAD | 0.0% |
| 2005 Q4 | - CAD | 0.0% |
| 2005 Q1 | - CAD | 0.0% |
| 2005 Q2 | - CAD | 0.0% |
| 2005 FY | - CAD | 0.0% |
| 2005 Q3 | - CAD | 0.0% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q4 | - CAD | 0.0% |
| 2004 Q3 | - CAD | 0.0% |
| 2004 Q2 | - CAD | 0.0% |
| 2004 FY | - CAD | 0.0% |
| 2003 FY | - CAD | 0.0% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 0.0% |
| 2003 Q3 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 79.914% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -100.778% |
| SQZ Biotechnologies Company | 27.47 Million USD | 69.874% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 80.919% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 72.198% |
| Mesoblast Limited | 118.7 Million USD | 93.028% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -772.743% |
| Genus plc | 233.1 Million USD | 96.45% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -182.419% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -515.962% |
| Marizyme, Inc. | 18.71 Million USD | 55.785% |
| ContraFect Corporation | 2.88 Million USD | -187.26% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1003.463% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6008.314% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -472.209% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -255.81% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -46.261% |
| MultiCell Technologies, Inc. | 202.58 USD | -4085185.319% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 85.604% |
| EV Biologics, Inc. | 1.49 Million USD | -453.669% |
| Q BioMed Inc. | 4.1 Million USD | -101.363% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 74.998% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1213.486% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -573.741% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1025.153% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 95.176% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 36.324% |
| Skye Bioscience, Inc. | 4.61 Million USD | -79.317% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -831.912% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -5747.999% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -40.961% |
| IMV Inc. | 28.88 Million USD | 71.347% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -32078.432% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -266.456% |
| GB Sciences, Inc. | 1.75 Million USD | -370.411% |
| Alpha Cognition Inc. | 1.22 Million USD | -578.151% |
| HST Global, Inc. | 98.31 Thousand USD | -8317.469% |
| CSL Limited | 12.18 Billion USD | 99.932% |
| Halberd Corporation | 150 Thousand USD | -5417.314% |
| Enzolytics Inc. | 996.33 Thousand USD | -730.639% |
| Resverlogix Corp. | 6.49 Million USD | -27.499% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1633.188% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3137.962% |
| argenx SE | 20 Million USD | 58.62% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 81.835% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -205.533% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -80838.592% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.019% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4025.28% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -245.159% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3509.375% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 87.765% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -173.478% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2200.734% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 59.288% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -5467.271% |
| BioStem Technologies, Inc. | 4.71 Million USD | -75.658% |
| ONE Bio Corp. | 19.71 Million USD | 58.022% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3207.98% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3227.425% |
| Agentix Corp. | 50 Thousand USD | -16451.942% |
| LadRx Corporation | 33.6 Thousand USD | -24526.468% |
| Cell Source, Inc. | 9.25 Million USD | 10.57% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -994.41% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -994.41% |
| NovAccess Global Inc. | 2.19 Million USD | -276.201% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -17.011% |
| Itoco Inc. | 228.37 Thousand USD | -3523.82% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3822.726% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -66.084% |
| Kadimastem Ltd | 891.22 Thousand USD | -828.605% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1959.473% |
| CytoDyn Inc. | 30.07 Million USD | 72.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1608.909% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2252.151% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -5.831% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -6655.895% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2569.668% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -74.773% |
| International Stem Cell Corporation | 4.17 Million USD | -98.085% |
| Bioxytran, Inc. | 1.92 Million USD | -329.921% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -13160.012% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -279.475% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 0.481% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 3.6% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -432.053% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2988.049% |
| Neutra Corp. | 54.15 Thousand USD | -15181.725% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -352.239% |
| PureTech Health plc | 25.51 Million USD | 67.56% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -576.017% |
| IXICO plc | 472.02 Thousand USD | -1653.298% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 46.61% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 86.708% |
| CSL Limited | 12.18 Billion USD | 99.932% |
| Cellectis S.A. | 92.77 Million USD | 91.08% |